baseclick GmbH is a start-up company funded and founded by BASF Venture Capital GmbH. It holds the intellectual property for the technologies and will offer this for licensing the technology, purchasing of their products, and cooperation for the further development of their technologies. The company has its seat in Tutzing, south of Munich, close to the biotech campus in Munich-Martinsried. The IP was generated at the University of Munich in the group of Prof. Thomas Carell and BASF SE. Two former members of his group joined the company from the beginning.

Pierre Fabre Médicament SA manufactures cosmetics and pharmaceutical products. It focuses on research, development, and prescription of medicines and cosmetics. The company was founded on December 31, 1982 and is headquartered in Boulogne-Billancourt, France.

Andremacon is committed to developing novel therapeutics that inhibit abnormal cell signaling pathways that drive cancer. Furthermore, they are working to combine drug candidates with genetic data and other diagnostic information in order to identify patients who are most likely to benefit.

Immune Disease Institute, Inc. provides biomedical research services. It engages in doing fundamental research to improve human health, harness inflammation, and strengthen immune defense. The company was founded on January 19, 1953 and is headquartered in Boston, MA.

Columbia University provides a hub for entrepreneurship-related information and programming.

InteRNA Technologies BV develops RNA technologies and applications. It provides drug discovery and development services for the treatment of cancer based on the proprietary microRNA (miRNA) functions. The company develops miRNA-based therapeutics that control genes connected in signal transduction pathways and biological processes as a part of cancer initiation, progression and metastasis. InteRNA Technologies was founded by Edwin Cuppen and Eugene Berezikov in December 2006 and is headquartered in Nijmegen, the Netherlands.

AptamiR Therapeutics is a biotechnology company that focuses on developing a revolutionary treatment for human obesity. Based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food, AptamiR is developing microRNA-targeted therapeutics that enhance thermogenesis, turning fat-storing white adipocytes into fat-burning adipocytes (brown-like, brite or beige). MicroRNAs are attractive drug candidates for complex diseases like obesity, as they can modulate the expression of gene networks. AptamiR is also developing drug delivery approaches that can specifically target microRNA modulators to adipose tissue. It provides treatment for human obesity by targeting peripheral white and brown adipose tissues and is based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or the intestinal absorption of food that enables patients to get the excess fat removed from their body. AptamiR Therapeutics was established in 2012 and is headquartered in Austin, Texas.

University Hospital Freiburg is a healthcare organization that offers research, education, clinical practice, and treatment programs. Freiburg University Medical Center ensures the possible care for their patients by bundling their knowledge from clinical practice, research, and teaching. Their scientific work aims at the responsible and at the same time rapid introduction of new therapies that save lives and maintain quality of life. Their university clinic offers the medical offspring limitless opportunities to expand their knowledge. It is founded in 1457 in Freiburg, Germany.

Assistance Publique des Hôpitaux de Paris SA the company is headquartered in Paris, France.

Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and New England Deaconess Hospital (founded in 1896). Among independent teaching hospitals, Beth Israel Deaconess Medical Center consistently ranks in the top three recipients of biomedical research funding from the National Institutes of Health. Research funding totals nearly $200 million annually. BIDMC researchers run more than 850 active sponsored projects and 200 clinical trials. The Harvard-Thorndike General Clinical Research Center, the oldest clinical research laboratory in the United States, has been located on this site since 1973.

Alnylam is the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases.

The Lee Co. supplies precision fluid control products to industries including aerospace, formula 1 racing, oil exploration, automotive and off-highway equipment, and medical and scientific instruments. Its products include precision microhydraulics and electro-fluidic systems. The company was founded by Leighton Lee II in 1948 and is headquartered in Westbrook, CT.

Part of Sirnaomics, Inc., Sirnaomics Biopharmaceuticals (Suzhou) Co., Ltd. is a company headquartered in Suzhou, China, that develops nucleic acid drugs. It was founded in 2008 by David Mark Evans and Yang Lu. Yang Lu has been the CEO since the inception date.

Sylentis is a biotech company founded in 2006 and wholly owned by Pharma Mar S.A. (PHM:SM), with the mission of building a solid and sustainable business and becoming a leader of a new class of medicines based on RNA interference or RNAi. RNAi is a promising approach to silence targets involved in many diseases and represents a new drug mechanism of action. The Sylentis pipeline is aimed at indications with an elevated market potential, including ocular pathologies, inflammatory diseases and central nervous system diseases. Given the inherent complications of this technology regarding delivery of the active principle to the target tissue, our strategy is based on first selecting accessible therapeutic targets, which don not require systemic administration of the product. However, the development of formulations for RNAi technology to increase the therapeutic effect of these molecules is an area of great interest to the company

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

PRAMOMOLECULAR is developing self-delivering siRNAs as therapeutic candidates for the treatment of lung and pancreatic cancers.

Jiangxi Zhonghong Boyuan Biotechnology Co., Ltd., established on 2015-01-19, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion,Big data service,Medical Research and Experimental Development,Business Management Consulting,Specialty Chemicals Sales(Free of Hazardous Chemicals)(Except for licensed business,Can independently operate projects that are not prohibited or restricted by laws and regulations)

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Shanghai Zechong Biotechnology Co., Ltd., established on 2021-09-08, Business scope includes general items:engaged in biotechnology,Technology development in the field of medical science and technology,technical consulting,Technical Services,technology transfer;Business Management Consulting;Sales of laboratory equipment and consumables.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license) licensed items:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)